Novo Nordisk A/ S stock faces analyst scrutiny amid Wegovy demand questions and Equal Weight rating hold

Barclays maintains Equal Weight on Novo Nordisk A/S stock (ISIN: DK0062498333) with a 270 DKK target, citing Iqvia data showing Wegovy uptake slightly above prior obesity drug launches but warning of underestimated true demand. The Novo Nordisk A/S stock trades on OMXCOP at around 238 DKK, reflecting recent pressures in the diabetes and obesity treatment leader. US investors eye pipeline risks and competition in a massive GLP-1 market.

Novo Nordisk A/S, the Danish pharmaceutical powerhouse behind blockbuster obesity drug Wegovy, is drawing fresh analyst attention as Barclays Capital holds its Equal Weight rating on the stock. On March 23, 2026, analyst James Gordon noted Iqvia data indicating Wegovy patient starts slightly exceeding those of previous obesity market entries. However, he cautioned that actual demand may be significantly underestimated, creating uncertainty around growth sustainability for this key revenue driver. The Novo Nordisk A/S stock was last seen on OMXCOP at 238.00 DKK, up 0.96% in the past 24 hours amid broader market dynamics.

As of: 24.03.2026

Dr. Elena Hartwell, Pharma Sector Lead Analyst: Novo Nordisk A/S exemplifies the high-stakes GLP-1 obesity market where demand surges meet execution challenges in scaling production and navigating competition.

Barclays Rating Hold Signals Cautious Outlook on Wegovy Momentum

Barclays Capital reiterated its Equal Weight stance on Novo Nordisk A/S stock with a price target of 270 DKK, as detailed in a note dated March 23, 2026. The firm highlighted Iqvia sales data for Wegovy, Novo Nordisk's semaglutide-based obesity injection, showing new patient initiations running modestly ahead of historical benchmarks from prior weight-loss drug launches. This development comes at a time when obesity treatments have become a multi-billion-dollar category, with Novo Nordisk holding a leading position alongside rivals like Eli Lilly.

James Gordon, the Barclays analyst, emphasized that while uptake appears solid, Novo Nordisk itself believes market forecasts underestimate true patient demand potential. This perspective underscores the company's confidence in Wegovy's long-term trajectory despite near-term supply constraints that have plagued scaling efforts. For investors, this rating hold reflects a balanced view: strong fundamentals tempered by valuation concerns after years of rapid gains.

The analysis arrives as Novo Nordisk navigates peak profitability questions in its diabetes franchise, where older insulins face generic erosion, shifting reliance toward high-margin GLP-1 agonists like Ozempic and Wegovy. Barclays' 270 DKK target implies limited near-term upside from current levels on OMXCOP, where the stock has pulled back from 2024 highs above 1,000 DKK.

Wegovy Data Breakdown: Uptake Above Peers but Demand Gap Persists

Iqvia's latest prescription tracking reveals Wegovy new patient starts tracking slightly above the pace seen during introductions of earlier obesity drugs, a positive signal for Novo Nordisk A/S market penetration. This metric captures real-world adoption in a category exploding due to rising obesity awareness and efficacy data from GLP-1 therapies. However, Novo Nordisk management has repeatedly argued that external estimates fail to capture pent-up demand, pointing to waitlists and supply bottlenecks as evidence.

These supply issues stem from complex peptide manufacturing requirements for semaglutide, Novo Nordisk's active ingredient across both Wegovy and diabetes drug Ozempic. The company has invested billions in capacity expansions, including new facilities in the US and Europe, but ramp-up lags persist. Barclays' note implicitly questions whether this demand-supply imbalance will resolve swiftly enough to justify premium valuations, contributing to the Equal Weight call.

Financially, Novo Nordisk reported FY revenue of 290.40 billion DKK and net income of 100.99 billion DKK, with EPS at 24.95 DKK, supporting a trailing P/E of 13.65 on OMXCOP shares. Dividend yield stands at 3.52%, appealing to income-focused holders amid growth moderation signals.

GLP-1 Market Dynamics: Novo Nordisk's Lead Under Pressure

Novo Nordisk A/S dominates the GLP-1 receptor agonist space, with Wegovy and Ozempic generating outsized revenue growth. The obesity market alone could exceed $100 billion annually by decade's end, driven by drugs offering 15-20% sustained weight loss. Yet competition intensifies from Eli Lilly's Mounjaro and Zepbound, which boast superior weight-loss profiles in head-to-head data.

Barclays' analysis implicitly weighs this rivalry, as Lilly gains share in both obesity and diabetes segments. Novo Nordisk counters with oral semaglutide candidates and next-gen molecules, but clinical timelines introduce uncertainty. Market cap hovers at 1.47 trillion DKK on OMXCOP, reflecting beta of 1.56 and float of 3.16 billion shares.

Pipeline breadth includes rare disease assets and cardiovascular outcomes data bolstering reimbursement cases globally. Still, patent cliffs loom for legacy insulins, pressuring margins if GLP-1 pricing faces headwinds from payers.

US Investor Angle: Massive Exposure via ADRs and ETFs

For US investors, Novo Nordisk A/S offers direct access through OTC ADRs under NONOF, mirroring OMXCOP Class B shares (ISIN DK0062498333). Heavy weighting in popular ETFs amplifies relevance: iShares MSCI EAFE ETF (EFA) holds 0.73%, Vanguard FTSE Europe ETF (VGK) 0.85%, and others like VEU and SCHF feature prominently. These vehicles provide low-cost entry for broad international exposure.

US market dynamics matter deeply, as America accounts for over half of Wegovy sales amid epidemic obesity rates. FDA approvals, payer negotiations, and supply chain localization efforts directly impact earnings. Recent capacity builds in North Carolina position Novo Nordisk for reduced import reliance, mitigating currency and geopolitical risks.

With European dividends tax-efficient via ADRs and growth tied to US healthcare spend, the stock fits portfolios seeking defensive healthcare with upside. Barclays' target translates to modest EUR upside from STU levels around 31-32 EUR.

Risks and Open Questions Weighing on the Stock

Key risks include manufacturing shortfalls persisting into 2026, potentially capping Wegovy revenue below demand peaks. Competition from Lilly's dual-agonist tech poses efficacy threats, while oral GLP-1 rivals could erode injection premiums. Regulatory scrutiny on side effects like gastrointestinal issues or thyroid risks adds compliance hurdles.

Valuation stretches post-rally, with P/E at 13.65 but forward multiples sensitive to guidance. Macro factors like DKK/EUR/USD swings affect reported figures, and China exposure introduces tariff uncertainties. Barclays' Equal Weight encapsulates these balanced risks against durable franchise moats.

Financial Snapshot and Forward Path

Novo Nordisk A/S boasts robust fundamentals: 290.40 billion DKK revenue, 100.99 billion DKK net profit, and 3.52% yield. Debt markets show stable funding via Eurobonds yielding 2.5-3.5% to 2034. Strategic focus remains pipeline execution, with oral obesity candidates in late-stage trials offering convenient alternatives.

US investors should monitor Q1 2026 earnings for Wegovy volume updates and guidance revisions. Barclays' view suggests consolidation before new catalysts emerge, positioning the stock as a hold in diversified portfolios.

Disclaimer: This is not investment advice. Stocks are volatile financial instruments.